Results 211 to 220 of about 272,686 (351)

Angiotensin II type 1 receptor (AGTR1; AT1R) [PDF]

Science-Business eXchange, 2009
openaire   +1 more source

Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation.

Journal of the American College of Cardiology, 2003
K. Kumagai, H. Nakashima, H. Urata, N. Gondo, Kikuo Arakawa, K. Saku   +5 more
semanticscholar   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

Autoantibodies directed against the angiotensin II type 1 receptor and the endothelin-1 type A receptor in patients with systemic sclerosis. [PDF]

RMD Open
van der Wouden KE, Ahmed S, van Oostveen WM, Hoekstra EM, Liem SIE, Huizinga TWJ, Toes REM, Voskuyl AE, Riemekasten G, Fehres CM, Vonk M, de Vries-Bouwstra JK.   +11 more
europepmc   +1 more source

Angiotensin II type 1 receptor localizes at the blood-bile barrier in humans and pigs. [PDF]

Histochem Cell Biol, 2022
Pryymachuk G, El-Awaad E, Piekarek N, Drebber U, Maul AC, Hescheler J, Wodarz A, Pfitzer G, Neiss WF, Pietsch M, Schroeter MM.   +10 more
europepmc   +1 more source

Renin; angiotensin II type 1 (AT1) receptor [PDF]

Science-Business eXchange, 2008
openaire   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Angiotensin II Type 1 Receptor Blocker Usage Prevents Oxidative Stress and Muscle Dysfunction in HIV. [PDF]

Fundam Clin Pharmacol
Deminice R, Cella PS, Borsari AL, Padilha CS, de Oliveira VHF.   +4 more
europepmc   +1 more source

Angiotensin II Type 1 Receptor Blocker Prevents Abdominal Aortic Aneurysm Progression in Osteoprotegerin-Deficient Mice via Upregulation of Angiotensin (1-7). [PDF]

J Am Heart Assoc, 2023
Karasaki K, Kokubo H, Bumdelger B, Kaji N, Sakai C, Ishida M, Yoshizumi M.   +6 more
europepmc   +1 more source

Type-1 Angiotensin II Receptor-Associated Protein [PDF]

, 2020
openaire   +1 more source